| | |

Could Viking Therapeutics Become the Next Eli Lilly?

ByMario Cazombo

The obesity treatment market is booming, with groundbreaking drugs like Eli Lilly‘s (NYSE: LLY) Zepbound delivering transformative patient results and powering its stock to a spectacular 400% return in the past five years. Amid this estimated $100 billion opportunity, much smaller upstart Viking Therapeutics (NASDAQ: VKTX) has emerged with a promising clinical pipeline, aiming to…

| | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | |

The HealthCare Sector: A Look At Sector Earnings Trends

ByMario Cazombo
| | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | |

abrdn Life Sciences Investors Q1 2025 Commentary

ByMario Cazombo
| | | |

3 American Growth Giants to Invest in for the Long Haul

ByMario Cazombo

Many of the best growth stocks in the world are based out of the U.S. This is the land of both opportunity and innovation. Warren Buffett has always been bullish on betting on the U.S. because he’s a big believer in American business. If you want to follow suit and invest in some of the…

| | |

Why Novo Nordisk Stock Just Popped

ByMario Cazombo

Over the weekend, President Trump offered to delay implementation of a new 50% tariff on imports from the European Union. The tariff, which was supposed to begin on June 1, now won’t take effect until July 9. Shares of Ozempic and Wegovy manufacturer Novo Nordisk (NYSE: NVO) reacted positively to the news and are up…